FDA Approves New Therapy for Metastatic Breast Cancer from Dana-Farber miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
One of the problems with the new subgroup of HER2 low tumors is that using current assays to measure low levels "is like weighing mice on a scale built for elephants," says one expert.
Using the Breast Cancer Index earlier could identify premenopausal HR+ breast cancer patients who benefit from ovarian function suppression, suggests analysis.
Targeted agents, combination therapies, and clinical trial equity headline Dana-Farber research miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
The agreement with Dana-Farber Cancer Institute consists of using HER2DX? to analyze tumor samples from more than 500 patients with early-stage HER2+ breast cancer across three clinical trials